Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 39,440 shares at $74.88 ($3.0M) on 2025-12-10, disclosed to the SEC on 2025-12-12.
Scheduled sale ($3.0M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.88 | 9,435 | $706K | 23.8% |
| 2 | $74.88 | 9,435 | $706K | 23.8% |
| 3 | $75.79 | 10,005 | $758K | 25.5% |
| 4 | $75.79 | 10,005 | $758K | 25.5% |
| 5 | $76.58 | 560 | $43K | 1.4% |
| Total | $75.37 avg | 39,440 |
| $3.0M |
| 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |